.. Les-modèle-de-maladie-de-parkinson-autosomique-dominante, 21 a. Modèles ?-syn, p.23

.. Les-modèle-de-maladie-de-parkinson-autosomique-récessive, 23 a. Modèles parkine, p.24

.. Mesure-de-la-largeur-de-la-zone-glomérulaire and B. Th-positives-dans-la-zone-glomérulaire-du, 30 4.5-Analyse de la fonction olfactive des rats30 b. Chez l'adulte, perception d'une odeur répulsive, p.31

.. Etude-de-la-voie-nigro-striée, 32 5.1-Analyse immunohistochimique, p.33

.. Etude-des-autres-structures, 35 6.1-Le locus coeruleus, ., p.36

Y. Agid, Are dopaminergic neurons selectively vulnerable to Parkinson's disease?, Advances in Neurology, vol.60, pp.148-164, 1993.

Y. Agid, Parkinson's disease: pathophysiology, The Lancet, vol.337, issue.8753, pp.1321-1324, 1991.
DOI : 10.1016/0140-6736(91)92989-F

B. P. Bejjani, Deep brain stimulation in Parkinson's disease: Opposite effects of stimulation in the pallidum, Movement Disorders, vol.13, issue.6, pp.969-970, 1998.
DOI : 10.1002/mds.870130618

A. Benabid, Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease, The Lancet Neurology, vol.8, issue.1, pp.67-81, 2009.
DOI : 10.1016/S1474-4422(08)70291-6

R. Betarbet, Animal models of Parkinson's disease, BioEssays, vol.395, issue.4, pp.308-318, 2002.
DOI : 10.1002/bies.10067

A. Bjorklund, Neural transplantation for the treatment of Parkinson's disease, The Lancet Neurology, vol.2, issue.7, pp.437-445, 2003.
DOI : 10.1016/S1474-4422(03)00442-3

F. Blandini and M. T. Armentero, Animal models of Parkinson???s disease, FEBS Journal, vol.6, issue.7, pp.1156-1166, 2012.
DOI : 10.1111/j.1742-4658.2012.08491.x

S. Blond and J. Siegfried, Thalamic Stimulation for the Treatment of Tremor and Other Movement Disorders, ActaNeurochirurgica,Supplementum, vol.52, pp.109-111, 1991.
DOI : 10.1007/978-3-7091-9160-6_30

D. Blum, Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease, Progress in Neurobiology, vol.65, issue.2, pp.135-172, 2001.
DOI : 10.1016/S0301-0082(01)00003-X

V. Bonifati, Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism, Science, vol.299, issue.5604, pp.256-259, 2003.
DOI : 10.1126/science.1077209

. E. Bowenkampk, Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons, The Journal of Comparative Neurology, vol.80, issue.4, pp.479-489, 1995.
DOI : 10.1002/cne.903550402

H. Braak, Gastric alpha-synuclein immunoreactive inclusions in Meissner's and, 2006.

H. Braak, Stages in the development of Parkinson???s disease-related pathology, Cell and Tissue Research, vol.16, issue.Suppl 2, pp.121-134, 2004.
DOI : 10.1007/s00441-004-0956-9

D. Branco, Cross-talk between mitochondria and proteasome in Parkinson???s disease pathogenesis, Frontiers in Aging Neuroscience, vol.2, p.17, 2010.
DOI : 10.3389/fnagi.2010.00017

J. Bures, O. Buresova, and J. Huston, Techniques and basic experiments for the study of brain and behavior, Book Chapter, 1984.

J. Cambier and M. Masson, Abrégé de neurologie, 1972.

K. R. Chaudhuri, Nocturnal symptom complex in PD and its management, Neurology, vol.61, issue.Issue 6, Supplement 3, pp.17-23, 2003.
DOI : 10.1212/WNL.61.6_suppl_3.S17

K. R. Chaudhuri and A. H. , Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, The Lancet Neurology, vol.8, issue.5, pp.464-474, 2009.
DOI : 10.1016/S1474-4422(09)70068-7

. Chenq, ??-Synuclein Alters Proteasome Function, Protein Synthesis, and Stationary Phase Viability, Journal of Biological Chemistry, vol.280, issue.34, pp.30009-30017, 2005.
DOI : 10.1074/jbc.M501308200

R. Cools, Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease, Neuroscience & Biobehavioral Reviews, vol.30, issue.1, pp.1-23, 2006.
DOI : 10.1016/j.neubiorev.2005.03.024

G. C. Cotzias, Parkinsonism and Dopa, Journal of Chronic Diseases, vol.22, issue.5, pp.297-301, 1969.
DOI : 10.1016/0021-9681(69)90072-1

T. M. Dawson, New Animal Models for Parkinson's Disease, Cell, vol.101, issue.2, pp.115-118, 2000.
DOI : 10.1016/S0092-8674(00)80629-7

T. M. Dawson, Genetic Animal Models of Parkinson's Disease, Neuron, vol.66, issue.5, pp.646-661, 2010.
DOI : 10.1016/j.neuron.2010.04.034

D. Lau, L. Et-breteler, and M. M. , Epidemiology of Parkinson's disease, The Lancet Neurology, vol.5, issue.6, pp.525-535, 2006.
DOI : 10.1016/S1474-4422(06)70471-9

A. Delmas, Voies et centres nerveux, 9ème édition, 1970.

D. Mattei and M. , Neuromelanic pigment in substantianigra neurons of rats and dogs, Neuroscience Letters, vol.3, issue.72, pp.37-42, 1986.

P. Derkinderen and M. , [Dyskinesia caused by L-DOPA], Revue Neurologique, vol.158, issue.1, pp.92-101, 2002.

F. D. Dick, Parkinson's disease and pesticide exposures, British Medical Bulletin, vol.79, issue.1, pp.219-231, 2006.
DOI : 10.1093/bmb/ldl018

D. W. Dickson and H. Braak, Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria, The Lancet Neurology, vol.8, issue.12, pp.1150-1157, 2009.
DOI : 10.1016/S1474-4422(09)70238-8

F. Javoy, Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system, Brain Research, vol.102, issue.2, pp.201-215, 1976.
DOI : 10.1016/0006-8993(76)90877-5

J. Hallman, Modulation of 6-hydroxydopamine induced alteration of the postnatal development of central noradrenaline neurons, Brain Research Bulletin, vol.9, pp.1-6, 1982.

R. Katzenschlager, Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study, Journal of Neurology, Neurosurgery & Psychiatry, vol.75, issue.12, pp.1672-1677, 2004.
DOI : 10.1136/jnnp.2003.028761

D. Kirik, Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system, The Journal of Neuroscience, vol.22, issue.7, pp.2780-2791, 2002.

D. Kirik, Nigrostriatal ??-synucleinopathy induced by viral vector-mediated overexpression of human ??-synuclein: A new primate model of Parkinson's disease, Proceedings of the National Academy of Sciences, vol.100, issue.5, pp.2884-2889, 2003.
DOI : 10.1073/pnas.0536383100

T. Kitada, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, vol.392, issue.6676, pp.605-608, 1998.

J. H. Kordower, Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease, New England Journal of Medicine, vol.332, issue.17, pp.1118-1124, 1995.
DOI : 10.1056/NEJM199504273321702

P. T. Kotzbauer, Fibrillization of ?-synuclein and tau in familial Parkinson's disease caused by the A53T ?-synuclein mutation, Experimental Neurology, vol.187, issue.2, pp.279-288, 2004.
DOI : 10.1016/j.expneurol.2004.01.007

P. Krack, Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease, The Lancet, vol.350, issue.9092, p.1676, 1997.
DOI : 10.1016/S0140-6736(05)64273-0

S. Kriks, Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson???s disease, Nature, vol.23, issue.7378, pp.547-51, 2011.
DOI : 10.1038/nature10648

E. K. Richfield, Behavioral and Neurochemical Effects of Wild-Type and Mutated Human ??-Synuclein in Transgenic Mice, Experimental Neurology, vol.175, issue.1, pp.35-48, 2002.
DOI : 10.1006/exnr.2002.7882

. Royal and . Key, Development of P2 olfactory glomeruli in P2-internal ribosome entry sitetau-LacZ transgenic mice, The Journal of Neuroscience, vol.19, issue.22, pp.9856-9864, 1999.

M. C. Rodriguez-oroz, Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms, The Lancet Neurology, vol.8, issue.12, pp.1128-1139, 2009.
DOI : 10.1016/S1474-4422(09)70293-5

J. Sachs, Effects of 6-hydroxydopamine on central noradrenaline neurons during ontogeny, Brain Research, vol.99, issue.2, pp.277-291, 1975.
DOI : 10.1016/0006-8993(75)90029-3

T. Schallert, Excessive bracing reactions and their control by atropine and l-DOPA in an animal analog of parkinsonism, Experimental Neurology, vol.64, issue.1, pp.33-43, 1979.
DOI : 10.1016/0014-4886(79)90003-7

A. H. Schapira, Science, medicine, and the future: Parkinson's disease, BMJ, vol.318, issue.7179, pp.311-314, 1999.
DOI : 10.1136/bmj.318.7179.311

. Singleton, ??-Synuclein Locus Triplication Causes Parkinson's Disease, Science, vol.302, issue.5646, p.841, 2003.
DOI : 10.1126/science.1090278

K. Steece-collier, Etiology of Parkinson's disease: Genetics and environment revisited, Proceedings of the National Academy of Sciences, vol.99, issue.22, pp.13972-13974, 2002.
DOI : 10.1073/pnas.242594999

R. R. Tasker, Pallidal and Thalamic Surgery for Parkinson's Disease, Experimental Neurology, vol.144, issue.1, pp.35-40, 1997.
DOI : 10.1006/exnr.1996.6385

E. Tolosa, The premotor phase of Parkinson's disease, Parkinsonism & Related Disorders, vol.13, pp.2-7, 2007.
DOI : 10.1016/j.parkreldis.2007.06.007

U. Ungerstedt, 6-hydroxy-dopamine induced degeneration of central monoamine neurons, European Journal of Pharmacology, vol.5, issue.1, pp.107-110, 1968.
DOI : 10.1016/0014-2999(68)90164-7

U. Ungerstedt, 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome, Pharmacology & Therapeutics. Part B: General and Systematic Pharmacology, vol.2, issue.1, pp.37-40, 1976.
DOI : 10.1016/0306-039X(76)90016-7

. Valente, PINK1 mutations are associated with sporadic early-onset parkinsonism, Annals of Neurology, vol.56, issue.3, pp.336-341, 2004.
DOI : 10.1002/ana.20256

C. Winkler, l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function, Neurobiology of Disease, vol.10, issue.2, pp.165-186, 2002.
DOI : 10.1006/nbdi.2002.0499

B. Winner, Mutant ??-synuclein exacerbates age-related decrease of neurogenesis, Neurobiology of Aging, vol.29, issue.6, pp.913-925, 2008.
DOI : 10.1016/j.neurobiolaging.2006.12.016

B. Winner, Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb, Experimental Neurology, vol.197, issue.1, pp.113-121, 2006.
DOI : 10.1016/j.expneurol.2005.08.028

E. Wolters, Non-motor extranigral signs and symptoms in Parkinson's disease, Parkinsonism & Related Disorders, vol.15, issue.3, pp.6-12, 2009.
DOI : 10.1016/S1353-8020(09)70770-9